Arda Therapeutics develops targeted cell depletion therapies that identify and selectively eliminate pathogenic cells via a single-cell-based discovery engine. Its platform detects disease-driving cells and their surface markers to enable targeted biologics that spare healthy tissue. The company positions this approach as applicable across fibrotic conditions (including pulmonary fibrosis), autoimmune and metabolic disorders. Arda aims to progress lead programs toward the clinic and expand its platform to additional disease areas. The company recently appointed Scott Turner, Ph.D., as chief scientific officer to advance fibrosis and biomarker strategies. Arda announced a $43 million Series A to fund clinical progression and platform expansion.

Total raised

$43M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2024